Autoimmune cytopenia

Hello!  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.  Please help us by filling it out!  Link: http://j.mp/2BlBaoQ

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Section editors
	Shruti Chaturvedi, MD, MSCI Baltimore, MD LinkedIn		Benjamin Tillman, MD Nashville, TN

2 regimens on this page 2 variants on this page

This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.

Relapsed or refractory

Alemtuzumab monotherapy

back to top

Regimen

Study	Evidence	Efficacy
Willis et al. 2001	Phase II	ORR: 71%

Immunosuppressive therapy

• Alemtuzumab (Campath) as follows:
  • Test dose: 1 mg IV over 60 minutes once
  • Days 1 to 10: 10 mg IV over 4 hours once per day

10-day course

References

1. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains verified protocol PubMed

Sirolimus monotherapy

back to top

Regimen

Study	Evidence
Bride et al. 2015	Phase II

Immunosuppressive therapy

• Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
  • See manuscript for recommended dose adjustments

6-month course, extended for those with a favorable response

References

1. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains protocol PubMed